Lynn is a biotech entrepreneur and the Founder and CEO of STALICLA. Driven by her lifelong involvement with the ASD community, Lynn has instituted a paradigm shift in the NDD drug discovery space with the creation of the first NDD specific precision medicine platform. Her passion and determination have defined STALICLA as pioneers in NDD and, more recently, neuropsychiatric treatments. Lynn has extensive experience in business development and healthcare that she gained through successive positions working for the World Economic Forum, healthcare venture initiatives in the Lemanic area and at the Faculty of Medicine of the University of Geneva. Lynn is an inventor or co-inventor of 11 patents and the recipient of a brain Foundation award for “outstanding leadership towards the advancement of treatments for patients Neurodevelopmental disorders”. She is a recognized thought leader in the precision psychiatry space and a reviewer for Biological Psychiatry.